Different HIV/SIV vaccine vectors expressing the same viral antigens can elicit disparate T-cell responses. Within this spectrum, replicating variable vaccines like SIVmac239?nef appear to generate pa
All data are median (interquartile range); All comparisons were made to FI/II: *p≤0.05, **p≤0.01 and ***p≤0.001; CHI: Chronically HIV-infected patients; DR: HLA-DR. Percentage of activated (HLA-DR+CD3
HIV-1 infection of monocyte-derived macrophages does not elicit a detectable type I IFN response in vitro, however, previously published data has shown that blocking STAT1 and STAT3 inhibits HIV-1 rep
Samples (listed vertically) were assessed at 1- and 3- years post-diagnosis. Breadth indicates the percentage of viruses neutralized from the panel of 34 diverse viruses (listed at top horizontally) w